Shearman & Sterling LLP
12/22/2023 | Press release | Distributed by Public on 12/21/2023 19:23
HighTide Therapeutics, Inc.’s HK$278.2 million IPO
NewsDecember 22, 2023
HighTide Therapeutics, Inc.'s HK$278.2 million IPO
Shearman & Sterling advised UBS Securities Hong Kong Limited and Huatai Financial Holdings (Hong Kong) Limited (Huatai) as the joint sponsors, and UBS AG Hong Kong Branch, Huatai and CLSA Limited as the overall coordinators of the initial public offering and listing of HighTide Therapeutics, Inc. (together with its subsidiaries, HighTide) on The Stock Exchange of Hong Kong Limited. The initial public offering raised net proceeds of approximately HK$194.1 million.
Established in 2011, HighTide is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. HighTide's core product, HTD1801, is a new molecular entity with the potential to become a therapy for NASH, T2DM, and other metabolic and digestive diseases.
The Team